ARTICLE | Company News
AstraZeneca, Millendo Therapeutics deal
January 11, 2016 8:00 AM UTC
AstraZeneca granted Millendo exclusive, worldwide rights to develop and commercialize MLE4901 ( AZD4901). The neurokinin 3 (NK3) receptor ( TACR3; NK3R) antagonist has completed a Phase IIa trial t...